Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.3
Journals
JCM
Special Issues
Treatment of Atopic Dermatitis, 2nd Edition
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Treatment of Atopic Dermatitis, 2nd Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 25 December 2026 | Viewed by 691

Editors

Dr. Francisco José Navarro-Triviño

E-Mail Website
Guest Editor
Contact Eczema and Immunoallergic Diseases, Dermatology Department, Hospital Universitario San Cecilio, Avda. del Conocimiento s/n, 18016 Granada, Spain
Interests: atopic dermatitis; biological therapy; JAK inhibitors
Special Issues, Collections and Topics in MDPI journals
Dr. Ricardo Ruíz-Villaverde

E-Mail
Guest Editor
Dermatology Department, San Cecilio University Hospital, 18016 Granada, Spain
Interests: atopic dermatitis; topical treatment; systemic treatment; biological therapy; JAK inhibitors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is my pleasure to invite you to contribute a paper to this Special Issue, entitled “Treatment of Atopic Dermatitis, 2nd Edition”, following on from the first edition wherein we published eight papers. For more details, please visit: https://www.mdpi.com/journal/jcm/special_issues/KD1THSMO7W.

Atopic dermatitis is a chronic inflammatory skin disease. Advances in the discovery of new therapeutic targets have allowed for the development of molecules with therapeutic potential. The reality is that there is a therapeutic paradigm shift in atopic dermatitis; therefore, it is necessary to stay updated in relation to the results observed in real clinical practice experience. It is also necessary to learn about new clinical trials and new potentially therapeutic molecules; for example, biological therapy promises new additions such as nemolizumab or lebrikizumab. Currently, new JAK inhibitors are being studied, although none appear to be ready to be incorporated in the short term. This special edition, titled Treatment of Atopic Dermatitis, will attempt to cover the scope of any potentially useful treatment for this disease.

Dr. Francisco José Navarro-Triviño
Dr. Ricardo Ruíz-Villaverde
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atopic dermatitis
  • eczema
  • topical treatment
  • systemic treatment
  • biological therapy
  • JAK inhibitor
  • antipruritic treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

12 pages, 1547 KB  
Review
The Western Japan Atopic Dermatitis Registry (WJADR): A Multicenter Real-World Registry of Systemic Therapies for Atopic Dermatitis
by Kazuhiko Yamamura, Shu Yotsumoto, Emi Sato, Sakae Kaneko, Yutaka Hatano, Shinichi Imafuku and Takeshi Nakahara
J. Clin. Med. 2026, 15(13), 5232; https://doi.org/10.3390/jcm15135232 - 4 Jul 2026
Viewed by 484
Abstract
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease with substantial impact on quality of life. The introduction of biologics and Janus kinase (JAK) inhibitors has markedly transformed systemic treatment strategies. However, long-term prospective real-world registries evaluating drug survival, safety, phenotype-specific [...] Read more.
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease with substantial impact on quality of life. The introduction of biologics and Janus kinase (JAK) inhibitors has markedly transformed systemic treatment strategies. However, long-term prospective real-world registries evaluating drug survival, safety, phenotype-specific treatment response, and post-discontinuation outcomes remain limited, particularly in Asian populations. Methods: The Western Japan Atopic Dermatitis Registry (WJADR) is a multicenter, prospective, observational registry coordinated by Kyushu University and collaborating institutions across western Japan. Patients initiating or currently receiving systemic therapy for AD are enrolled. Longitudinal data collection includes clinical phenotype classification, disease course classification, treatment exposure, physician-assessed severity scores, patient-reported outcomes, biomarkers, and safety information. The primary outcome is drug survival, while secondary outcomes include clinical improvement, adverse events, phenotype–treatment interactions, biomarker–treatment correlations, and treatment-switch patterns. Results: WJADR was designed as a phenotype-integrated real-world registry to evaluate comprehensive systemic treatment strategies and post-discontinuation outcomes in AD prior to the completion of patient enrollment and outcome analyses. Unlike existing registries primarily focused on biologic initiator cohorts or treatment burden, WJADR integrates clinical phenotypes, biomarkers, and longitudinal outcomes to support precision medicine approaches. Conclusions: WJADR represents the first large-scale multicenter prospective AD registry in western Japan and may provide ethnicity-specific real-world evidence to support long-term safety evaluation, treatment optimization, and phenotype-guided therapeutic strategies in AD. Full article
(This article belongs to the Special Issue Treatment of Atopic Dermatitis, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop